 Aveo Pharmaceuticals Inc. NASDAQ: AVEO shares are trading higher Thursday after the company received FDA approval for Fotivda for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma on Wednesday evening. After a higher open Thursday morning, the stock was down 15.58 at 12.90 at last check. 